Research ArticleHuman Studies
Somatostatin Receptor Imaging with Indium-111-Pentetreotide in Gastroenteropancreatic Neuroendocrine Tumors: Safety, Efficacy and Impact on Patient Management
François Jamar, René Fiasse, Norbert Leners and Stanislas Pauwels
Journal of Nuclear Medicine April 1995, 36 (4) 542-549;
François Jamar
René Fiasse
Norbert Leners


This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Somatostatin Receptor Imaging with Indium-111-Pentetreotide in Gastroenteropancreatic Neuroendocrine Tumors: Safety, Efficacy and Impact on Patient Management
François Jamar, René Fiasse, Norbert Leners, Stanislas Pauwels
Journal of Nuclear Medicine Apr 1995, 36 (4) 542-549;
Jump to section
Related Articles
- No related articles found.
Cited By...
- Endocrine Tumours: Epidemiology of malignant digestive neuroendocrine tumours
- The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0
- Detection of Liver Metastases From Endocrine Tumors: A Prospective Comparison of Somatostatin Receptor Scintigraphy, Computed Tomography, and Magnetic Resonance Imaging
- Molecular Imaging as In Vivo Molecular Pathology for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Follow-Up After Therapy
- Long-Term Efficacy of High-Activity 111In-Pentetreotide Therapy in Patients with Disseminated Neuroendocrine Tumors
- Detection of Neuroendocrine Tumors: 99mTc-P829 Scintigraphy Compared with 111In-Pentetreotide Scintigraphy
- Peptide Receptor Imaging and Therapy